Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.

Molecular bioSystems - 1 Oct 2012

Zhang Jingxian, Jia Jia, Zhu Feng, Ma Xiaohua, Han Bucong, Wei Xiaona, Tan Chunyan, Jiang Yuyang, Chen Yuzong

Abstract excerpt

Some drugs, such as anticancer EGFR tyrosine kinase inhibitors, elicit markedly different clinical response rates due to differences in drug bypass signaling as well as genetic variations of drug target and downstream drug-resistant genes. The profiles of these bypass signaling are expected to be useful for improved drug response prediction, which have not been systematically explored previously. In this work, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Lapatinib

Share to Predictive Value of Tests

Share to Quinazolines

Share to Support Vector Machine

Source

Identifiers

PMID: 22833077
DOI: 10.1039/c2mb25165e

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.PMID 22833077Read ↗

Identification of biomarkers, pathways and potential therapeutic targets for EGFR-TKI resistance in non-small-cell lung cancerSemantic proximity Read ↗

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.Semantic proximity Read ↗

Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancerSemantic proximity Read ↗

EGFR-TKIs resistance via EGFR-independent signaling pathways.Semantic proximity Read ↗

Identification of a gefitinib resistance-associated signature for predicting prognosis and therapeutic response in lung adenocarcinoma via integrated multi-omics analysis and machine learningSemantic proximity Read ↗

Pathway-extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitorsSemantic proximity Read ↗

Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted TherapySemantic proximity Read ↗

New Directions for Advanced Targeting Strategies of EGFR Signaling in CancerSemantic proximity Read ↗

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted TherapiesSemantic proximity Read ↗

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancerSemantic proximity Read ↗

Mapping the Pathways of Resistance to Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.